Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
International Journal of Cardiology. Heart & Vasculature|April 10, 2026
Dual-chamber pacing for vasovagal syncope: A systematic review and meta-analysis of randomized controlled trialsFrancesco Sbarra, Gianluca Pagnoni, Susan Darroudi, et al.
Minerva Obstetrics and Gynecology|May 14, 2021
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosisFrancesca Monari, Giovanni Grandi, Isotta Guidotti, et al.
BMC Cancer|May 15, 2020
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trialsClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.
International Journal of Clinical Oncology|February 22, 2012
Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypesFabrizio Nelli, Luca Moscetti, Guido Natoli, et al.
World Journal of Gastroenterology|August 1, 2013
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancerVanja Vaccaro, Emilio Bria, Isabella Sperduti, et al.
Biomedicines|January 21, 2023
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesKrisida Cerma, Federico Piacentini, Luca Moscetti, et al.
Clinical Breast Cancer|September 29, 2023
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-AnalysisRaffaella D'Onofrio, Isabella Sperduti, Federico Piacentini, et al.
Clinical Colorectal Cancer|July 25, 2008
A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicitiesTeresa Gamucci, Fabrizio Nelli, Giovanni Cianci, et al.
BMC Cancer|June 7, 2022
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysisClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.
JCO Global Oncology|July 1, 2025
Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last DecadeEmma Zattarin, Luca Moscetti, Elisa D'Agostino, et al.
Pageof 10